HeartFlow

HeartFlow focuses on precision heart care, combining human ingenuity with technology. HeartFlow’s non-invasive HeartFlow FFRCT Analysis leverages artificial intelligence to create a personalized three-dimensional model of the heart. Clinicians can use this model to evaluate the impact a blockage has on blood flow and determine the best treatment for patients. HeartFlow’s technology is reflective of our Silicon Valley roots and incorporates over two decades of scientific evidence with the latest advances in artificial intelligence. The HeartFlow FFRCT Analysis is commercially available in the United States, UK, Canada, Europe, and Japan.

HeartFlow headquartered in United States, North America, operates in the Biotechnology, Artificial Intelligence (AI), Health Care, Medical, Health Diagnostics sector. The company focuses on Biotechnology and has secured $174.4B in funding across 220 round(s). With a team of 251-500 employees, HeartFlow is actively contributing to advancements in Biotechnology. Their latest funding round, Series C - HeartFlow, raised $104.7M. Discover more about their projects, partnerships, and impact on our platform.